TREATMENT OF LOW-GRADE GLIOMA WITH MIRDAMETINIB

The present disclosure relates to a method of treating a patient (e.g., a human patient) who has low-grade glioma by administering (e.g., orally) mirdametinib, or a pharmaceutically acceptable salt thereof, to the patient.

Saved in:
Bibliographic Details
Main Authors Rankovic, Zoran, Robinson, Giles, Baker, Suzanne, Freeman, Burgess
Format Patent
LanguageEnglish
Published 21.09.2023
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present disclosure relates to a method of treating a patient (e.g., a human patient) who has low-grade glioma by administering (e.g., orally) mirdametinib, or a pharmaceutically acceptable salt thereof, to the patient.
Bibliography:Application Number: US202318185268